跳至主要内容
临床试验/NCT02216747
NCT02216747Unknown4 期

Treatment of Nephrotic Syndrome Relapse With Low Steroid Dose

Rabin Medical Center1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2014年9月最近更新:
适应症
干预措施

试验速览

阶段
4 期
入组人数
100
试验地点
1
主要终点
Nephrotic Syndrome Remission

研究概览

简要总结

Background- Idiopathic Nephrotic syndrome is the common glomerular disease in childhood. conventional treatment is steroid treatment and nearly 90% response to this treatment well.

Response to this treatment is the most important prognostic factor and this patients has a benign disease course.

60-70% among patients that response to steroid treatment,will suffer a relapse of NS.repeated steroids courses can lead to serious adverse events in children such as low bone density,weight gain ,growth slow down ,elevated blood pressure and eye pressure.there is side effect corelation between steroid dose and treatment duration.

guidelines for steroid dose for NS relapse are not based on retrospective clinical research but only on Nephrologists and experts opinion.

Rational- What would be the optimal low dose steroids and the shortest time of treatment in Nephrotic syndrome relapse?

详细描述

Idiopathic nephrotic syndrome in children is the most common chronic glomerular disease. The first line of therapy is prednisone and about 90% of the patients will

response to this treatment. The course of the disease is characterized of

recurrent relapses and repeated prednisone therapy. While prednisone doses and

therapy duration in the disease diagnosis has been based on multiple prospective

studies, the dose and therapy duration in the relapses was never challenged in a

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
1 Year 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with Idiopathic nephrotic syndrome with a flair that needs steroids treatment.

排除标准

  • Steroid resistance or treatment with Cyclosporin or Cellcept

研究组 & 干预措施

prednisone 60 mg/meter square Body Surface Aera

Active Comparator

A - 60 mg Prednisone/meter square Boby Surface Area( 30 twice)/day until there are 3 days of undetected protein in urine and tapering down to 40 mg ,30 mg, 20 mg ,10 mg and 5 mg and end.

干预措施: prednisone 60 mg/meter square Body Surface Area (Drug)

prednisone 45 mg/meter square BSA

Active Comparator

B- 45 mg prednisone / day until there are 3 days of undetected protein in urine and then 30 mg / day for two weeks and to 30,20,10,5 mg until treatment is ended.

干预措施: prednisone 45 mg (Drug)

prednisone 30 mg/meter squer BSA

Active Comparator

C- treatment of twice daily prednisone 30 mg per day until there are 3 days of undetectible protein in urine and then tapering down to 20 ,10 ,5 until treatment is ended.

干预措施: prednisone 30 mg (Drug)

结局指标

主要结局

Nephrotic Syndrome Remission

时间窗: 3 days

Undetectable protein in urine for 3 days

次要结局

  • Remission duration(Weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Amit Dagan

DR. Amit Dagan

Rabin Medical Center

研究点 (1)

Loading locations...

相似试验

Low Dose Steroids in the Treatment of Nephrotic... | 临床试验